disease-modifying therapies

R&D

The Parkinson's disease field is increasingly moving toward biologically defined disease frameworks using molecular biomarkers.

News

Bayer has joined the ranks of pharma groups planning major facility investments in the US, with a $2.2bn plan for a new production unit in Ohio.

Digital

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.